TP53 mutation is near-universal in high-grade serous ovarian (~96%). Not actionable per s...
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
| ID | BMA-TP53-MUT-OVARIAN |
|---|---|
| Type | Actionability |
| Status | reviewed 2026-04-27 | pending_clinical_signoff | actionability review required |
| Diseases | DIS-OVARIAN |
| Sources | SRC-CIVIC SRC-ESMO-OVARIAN-2024 SRC-NCCN-OVARIAN-2025 |
Actionability Facts
| Biomarker | BIO-TP53-MUTATION |
|---|---|
| Variant | any pathogenic mutation OR del(17p) |
| Disease | DIS-OVARIAN |
| ESCAT tier | IIIA |
| Recommended combinations | bevacizumab + carbo/pacli (1L HGSOC), niraparib maintenance (BRCA-WT/HRD-test) |
| Evidence summary | TP53 mutation is near-universal in high-grade serous ovarian (~96%). Not actionable per se; defines the disease phenotype. Niraparib/olaparib (HRD-positive) and bevacizumab combos drive 1L choices instead. |
Notes
ESCAT IIIA. Gene-level cell — biallelic vs monoallelic distinction matters in MDS/AML (biallelic = TP53-multihit per IPSS-M / ICC 2022, far worse). Per-hotspot cells provided for the most common variants.
Used By
No reverse references found in the YAML corpus.